Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

Initiative to Reduce Narcotic Prescribing in Robotic Nephrectomy
Is Immunotherapy With Cytoreductive Surgery Feasible in Metastatic Kidney Cancer?
Atezolizumab Plus Bevacizumab for Sarcomatoid Metastatic Renal Cell Carcinoma
FDA Approves Bevacizumab Biosimilar in Metastatic Renal Cell Carcinoma
ASCO 2019: Trial Update on Cytoreductive Nephrectomy for Intermediate-Risk Metastatic Renal Cancer
ASCO 2019: Enfortumab Vedotin in Advanced Urothelial Cancer
Dalantercept Plus Axitinib in Advanced Clear Cell Kidney Cancer
ASCO 2019: Does Adding Bevacizumab to Standard Treatment Improve Survival in Urothelial Carcinoma?
ASCO 2019: KEYNOTE-426 Subgroup Analysis of Pembrolizumab Plus Axitinib in Kidney Cancer
ASCO 2019: Pazopanib After Metastasectomy in Renal Cell Carcinoma
Spontaneous Shrinkage in Renal Cell Carcinoma Tumors
AUA 2019: Timing of Nephrectomy and Outcomes in pT3 Renal Cell Carcinoma
Combination of Avelumab/Axitinib Approved by FDA for Advanced Renal Cell Carcinoma
Rare Benign Mass Mimics Recurrent Renal Cell Carcinoma: Case Report
Novel Approach to Predicting Adverse and Beneficial Effects of Immunologic Interventions
Immune-Related Adverse Events in Metastatic Kidney Cancer: A Sign of Treatment Success?
FDA Approves Pembrolizumab Plus Axitinib in Advanced Kidney Cancer
Does Bladder-Sparing Therapy Plus Vinorelbine Improve Survival in Cisplatin-Ineligible Patients?
Accelerated FDA Approval Granted to Erdafitinib for Metastatic Urothelial Carcinoma
AACR 2019: Can B Cells Predict Response to Immunotherapy in Renal Cell Carcinoma?
EAU Congress 2019: Early Menopause in Smokers and Bladder Cancer Risk
Tumor-Lysis Syndrome in Patients With Genitourinary Cancers
Nivolumab in Metastatic Kidney Cancer in ‘Real-World Setting’
Predicting Outcomes With Lung Immune Prognostic Index
Postoperative Chemotherapy Plus Radiotherapy for Locally Advanced Bladder Cancer
2019 GU Symposium: Subgroup Analysis of Avelumab + Axitinib in JAVELIN Renal 101 Trial
2019 GU Symposium: Tivozanib Versus Sorafenib in Advanced Renal Cell Carcinoma
Priority Review Granted to Pembrolizumab Combination in First-Line Therapy for Advanced Kidney Cancer
FDA Accepts for Priority Review Avelumab and Axitinib Combination for Advanced Kidney Cancer
2019 GU Symposium: Cabozantinib vs. Everolimus in METEOR Trial of Kidney Cancer
2019 GU Symposium: Pembrolizumab Plus Axitinib Versus Sunitinib in Advanced Kidney Cancer
Risk Factors for Renal Cell Carcinoma Related to Obesity
Computer-Designed Protein Mimics Interleukin-2 With Less Toxicity
Kidney Cancer and Rare Genetic Tumor Syndrome
Sorafenib Versus Other Targeted Agents in Metastatic Renal Cell Carcinoma
Northwestern Medicine Receives $10 Million Gift to Create Urologic Cancer Institute


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.